The LoDAT study
Research type
Research Study
Full title
Comparison of low-dose and full-dose apixaban in combination with ticagrelor as dual antithrombotic therapy following percutaneous coronary intervention in patients with atrial fibrillation: the LoDAT study.
IRAS ID
1005589
Contact name
Robert Storey
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
ISRCTN Number
ISRCTN16600368
Research summary
Patients with the heart rhythm disturbance known as atrial fibrillation who have undergone stenting treatment of narrowed heart blood vessels, known as percutaneous coronary intervention or PCI, are often treated in our institution with two anticlotting drugs to prevent stroke and stent blockage, namely apixaban and ticagrelor. In this study, patients who provide informed consent will be randomised to either a standard dose of the anticlotting drug apixaban (5mg twice per day) plus a standard dose of ticagrelor (90mg twice per day), or apixaban at the lower dose of 2.5mg twice daily plus ticagrelor 90mg twice daily. The doses are taken up to a study visit at 26-28 days when a test known as skin bleeding time will be performed as well as blood tests to assess the effects of the anticlotting medication. After this visit, participants will continue standard anticlotting medication as recommended by the clinical care team and will be contacted by the research team by telephone after 14 days. The study will assess if low-dose apixaban, given alongside ticagrelor, reduces bleeding tendency compared with a standard dose of apixaban plus ticagrelor. The study will also described the anticlotting effects of the different regimens and provide pilot safety and efficacy data for dual antithrombotic therapy with low-dose apixaban and ticagrelor that may support further study of this treatment with a view to reducing the risk of bleeding complications.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
25/YH/0201
Date of REC Opinion
5 Nov 2025
REC opinion
Further Information Favourable Opinion